Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Elon Musk
Apple
Motorola
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Technology News / Pfizer, BioNTech say their COVID-19 vaccine is over 90% effective
Technology

Pfizer, BioNTech say their COVID-19 vaccine is over 90% effective

Pfizer, BioNTech say their COVID-19 vaccine is over 90% effective
Written by Siddhant Pandey
Nov 09, 2020, 07:18 pm 3 min read
Pfizer, BioNTech say their COVID-19 vaccine is over 90% effective

United States pharmaceutical giant Pfizer and German biotech firm BioNTech have said their COVID-19 vaccine is over 90% effective, according to initial data from a large study. The two drugmakers are the first to show successful data from a large-scale clinical trial for the vaccine. The novel coronavirus has infected 50.5 million people around the world and killed over 1.25 million.

Details
Analysis looked at first 94 infections among 43,000 volunteers

The initial analysis looked at first 94 confirmed cases among over 43,000 volunteers who either received two doses of the vaccine or placebo. Under 10% of infections were among participants who received the vaccine while over 90% of the infections were among people who received the placebo. The vaccine provided protection after seven days of the second dose (28 days after the first dose).

Emergency-use
Pfizer to seek emergency-use authorization from US FDA

Pfizer has said the firm plans to seek emergency-use authorization from the US Food and Drug Administration for people aged 16 to 85. For this, Pfizer will need to have collected two months of safety data after receiving the second dose of the vaccine. Pfizer is expecting this marker by the third week of November. FDA requires at least 50% efficacy from any vaccine.

Availability
50 million doses expected by 2020-end; 1.3 billion by 2021-end

If authorized for emergency-use, the number of doses will initially be limited. The companies had started manufacturing doses ahead of regulatory approval and are expected to produce 50 million doses by 2020-end—enough to vaccinate 25 million people. By the end of 2021, the companies hope to produce 1.3 billion doses. They notably have agreements with the US to provide up to 500 million doses.

Trials
Pfizer to continue trial until 164 participants contract infection

The Phase III trials of Pfizer's vaccine have enrolled 43,538 participants since July 27. Till Sunday, 38,955 of the volunteers had received a second dose of the vaccine. The firm has said 42% of international trial sites and 30% of US trial sites involve volunteers of racially/ethnically diverse backgrounds. Pfizer said it will continue the trial until there are 164 COVID-19 cases among participants.

Quote
'Significant step closer to providing people with much-needed breakthrough'

Pfizer CEO Albert Bourla said in a statement, "With today's news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis." Bourla added, "We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks."

Reaction
Experts say data 'impressive'; await complete results

William Schaffner—an infectious diseases expert at Vanderbilt University School of Medicine—told Reuters, "The efficacy data are really impressive. This is better than most of us anticipated." Schaffner said the data looks promising, even though the study isn't complete. Marylyn Addo—the head of tropical medicine at the University Medical Center Hamburg-Eppendorf—added, "Primary data are not yet available and a peer-reviewed publication is still pending."

Other vaccines
Several drugmakers race to develop COVID-19 vaccines

Separately, US-based Moderna Inc.—whose mRNA vaccine is another leading candidate—is expecting the results of its large-scale trial later this month. Meanwhile, the interim Phase III trial data for the Oxford University and AstraZeneca's vaccine candidate is expected as early as next month. This vaccine will be sold as 'Covishield' in India. India's indigenous COVAXIN—developed by Bharat Biotech—is expected to be ready by February 2021.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Siddhant Pandey
Siddhant Pandey
Twitter
Siddhant Pandey covers national and health news at NewsBytes. He has over five years of experience working as a multimedia journalist covering hard news in New Delhi. He was previously employed with The Indian Express and News World India and has juggled roles as a correspondent, copy editor, and video producer. He holds a Bachelor’s degree in Biotechnology from the Jaypee Institute of Information Technology, Noida.
Latest
Pfizer
Vaccine
United States of America
Coronavirus
BioNTech
Related
Latest
IPL 2022: Rajasthan Royals beat RCB to reach final
IPL 2022: Rajasthan Royals beat RCB to reach final Sports
2022 French Open: Leylah Fernandez progresses; Victoria Azarenka ousted
2022 French Open: Leylah Fernandez progresses; Victoria Azarenka ousted Sports
2022 French Open: Vintage Rafael Nadal marches on
2022 French Open: Vintage Rafael Nadal marches on Sports
No international link in Cordelia drugs case: NCB DG
No international link in Cordelia drugs case: NCB DG India
J&K: ED summons ex-CM Farooq Abdullah on May 31
J&K: ED summons ex-CM Farooq Abdullah on May 31 Politics
Pfizer
New Omicron sub-variants can trigger new COVID-19 wave: Study
New Omicron sub-variants can trigger new COVID-19 wave: Study World
'Cautious optimism' after initial Omicron studies; here's what we know
'Cautious optimism' after initial Omicron studies; here's what we know Technology
COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective
COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective Technology
COVID-19: India reports 10K+ infections; 301 more deaths
COVID-19: India reports 10K+ infections; 301 more deaths India
India may approve anti-COVID-19 drug molnupiravir soon: Report
India may approve anti-COVID-19 drug molnupiravir soon: Report India
More News
Vaccine
COVID-19: India logs 2,628 fresh cases, 18 more fatalities
COVID-19: India logs 2,628 fresh cases, 18 more fatalities India
COVID-19: India logs 2,124 fresh cases, 17 more deaths
COVID-19: India logs 2,124 fresh cases, 17 more deaths India
COVID-19: India logs 2,487 fresh cases, 13 more fatalities
COVID-19: India logs 2,487 fresh cases, 13 more fatalities India
COVID-19: India logs 2,858 fresh cases, 11 more fatalities
COVID-19: India logs 2,858 fresh cases, 11 more fatalities India
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon India
More News
United States of America
A look at deadliest school shootings; Texas leads the way
A look at deadliest school shootings; Texas leads the way World
Monkeypox: Maharashtra, Tamil Nadu, Rajasthan prepare to fight against virus
Monkeypox: Maharashtra, Tamil Nadu, Rajasthan prepare to fight against virus India
PM Modi meets Japanese IT giant head, discusses investment opportunities
PM Modi meets Japanese IT giant head, discusses investment opportunities World
Afghan women TV hosts cover faces after Taliban's diktat
Afghan women TV hosts cover faces after Taliban's diktat World
'Concerned' WHO expects more monkeypox cases globally
'Concerned' WHO expects more monkeypox cases globally World
More News
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
BioNTech
Pfizer-BioNTech vaccine 'safe' for kids aged 5-11; generates 'robust immunity'
Pfizer-BioNTech vaccine 'safe' for kids aged 5-11; generates 'robust immunity' World
England school children aged 12-15yrs to be offered COVID-19 vaccine
England school children aged 12-15yrs to be offered COVID-19 vaccine World
Pfizer-BioNTech's coronavirus vaccine being tested on children under 12
Pfizer-BioNTech's coronavirus vaccine being tested on children under 12 World
Johnson & Johnson's one-shot COVID-19 vaccine shows 66% strong efficacy
Johnson & Johnson's one-shot COVID-19 vaccine shows 66% strong efficacy Technology
Over 10 lakh inoculated, India's vaccination drive picks pace
Over 10 lakh inoculated, India's vaccination drive picks pace India
More News
Related
Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine
Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine World
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA World
Pfizer-BioNTech COVID-19 vaccine to get US-FDA's full approval next week
Pfizer-BioNTech COVID-19 vaccine to get US-FDA's full approval next week World
'Benefits outweigh risks'; UK clears Pfizer vaccine for ages 12-15
'Benefits outweigh risks'; UK clears Pfizer vaccine for ages 12-15 World
Next News Article
Next News Article

Love Technology news?

Subscribe to stay updated.

Science Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022